Screening and therapeutic management of lipoprotein(a) excess: Review of the epidemiological evidence, guidelines and recommendations

Clinica Chimica Acta

Volumn 412, Issue 11-12, 2011, Pages 797-801

  Lippi, Giuseppe ^a   Franchini, Massimo ^a   Targher, Giovanni ^b  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

Author keywords

Cardiovascular risk; Lipoprotein(a); Recommendations; Screening; Therapy

Indexed keywords

LIPOPROTEIN A; NICOTINIC ACID;

BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DRUG DOSE TITRATION; EPIDEMIOLOGICAL DATA; FALL RISK ASSESSMENT; GENOTYPE; HUMAN; HYPERLIPOPROTEINEMIA; LABORATORY TEST; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN POLYMORPHISM; REVIEW; SCREENING; VENOUS THROMBOEMBOLISM;

ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; LIPOPROTEIN(A); POLYMORPHISM, GENETIC; PRACTICE GUIDELINES AS TOPIC; VENOUS THROMBOEMBOLISM;

EID: 79954991685     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2011.01.018     Document Type: Review

References (31)

1. Berg K. A new serum type system in man - the Lp system. Acta Pathol Microbiol Scand 1963, 59:369-382.
2. Lippi G., Guidi G. Biochemical risk factors and patient's outcome: the case of lipoprotein(a). Clin Chim Acta 1999, 280:59-71.
3. Lippi G., Guidi G. Lipoprotein(a): an emerging cardiovascular risk factor. Crit Rev Clin Lab Sci 2003, 40:1-42.
4. Lippi G., Franchini M., Salvagno G.L., Guidi G.C. Lipoprotein[a] and cancer: anti-neoplastic effect besides its cardiovascular potency. Cancer Treat Rev 2007, 33:427-436.
5. McLean J.W., Tomlinson J.E., Kuang W.J., et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 1987, 330:132-137.
6. Kalina A., Császár A., Füst G., et al. The association of serum lipoprotein(a) levels, apolipoprotein(a) size and (TTTTA)(n) polymorphism with coronary heart disease. Clin Chim Acta 2001, 309:45-51.
7. Catalano M., Cortelazzo A., Yilmaz Y., Perilli E., Carzaniga G., Emanuele E. The LPA gene C93T polymorphism influences plasma lipoprotein(a) levels and is independently associated with susceptibility to peripheral arterial disease. Clin Chim Acta 2008, 387:109-112.
8. Zídková K., Kebrdlová V., Zlatohlávek L., Ceska R. Detection of variability in apo(a) gene transcription regulatory sequences using the DGGE method. Clin Chim Acta 2007, 376:77-81.
9. Lippi G., Braga V., Adami S., Guidi G. Modification of serum apolipoprotein A-I, apolipoprotein B and lipoprotein(a) levels after bisphosphonates-induced acute phase response. Clin Chim Acta 1998, 271:79-87.
10. Lippi G., Targher G., Franchini M. Lipoprotein(a), thrombophilia and venous thrombosis. Acta Haematol 2007, 117:246-247.
11. Lippi G., Arosio E., Prior M., Guidi G. Biochemical risk factors for cardiovascular disease in an aged male population: emerging vascular pathogens. Angiology 2001, 52:681-687.
12. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009, 302:412-423. Emerging Risk Factors Collaboration.
13. U.S.Preventive Services Task Force Using nontraditional risk factors in coronary heart disease risk assessment: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2009, 151:474-482.
14. Nordestgaard B.G., Chapman M.J., Ray K., et al. European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 2010, 31:2844-2853.
15. Helfand M., Buckley D., Fleming C., et al. Screening for Intermediate Risk Factors for Coronary Heart Disease [Internet] Oct 2009, Agency for Healthcare Research and Quality (US), Rockville (MD), Report No.: 10-05141-EF-1.
16. Smolders B., Lemmens R., Thijs V. Lipoprotein (a) and stroke: a meta-analysis of observational studies. Stroke 2007, 38:1959-1966.
17. Guidelines for the Primary Prevention of Stroke. A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 2011, 42:227-276. American Heart Association Stroke Council, Council on Cardiovascular Nursing, Council on Epidemiology and Prevention, Council for High Blood Pressure Research, Council on Peripheral Vascular Disease, and Interdisciplinary Council on Quali.
18. Kenet G., Lütkhoff L.K., Albisetti M., et al. Impact of thrombophilia on risk of arterial ischemic stroke or cerebral sinovenous thrombosis in neonates and children: a systematic review and meta-analysis of observational studies. Circulation 2010, 121:1838-1847.
19. Takagi H., Manabe H., Kawai N., Goto S.N., Umemoto T. Circulating lipoprotein(a) concentrations and abdominal aortic aneurysm presence. Interact Cardiovasc Thorac Surg 2009, 9:467-470.
20. Sofi F., Marcucci R., Abbate R., Gensini G.F., Prisco D. Lipoprotein (a) and venous thromboembolism in adults: a meta-analysis. Am J Med 2007, 120:728-733.
21. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 2009, 361:2518-2528. PROCARDIS Consortium.
22. Barlera S., Specchia C., Farrall M., et al. Multiple QTL influence the serum Lp(a) concentration: a genome-wide linkage screen in the PROCARDIS study. Eur J Hum Genet 2007, 15:221-227.
23. Clarke R., Xu P., Bennett D., et al. Lymphotoxin-alpha gene and risk of myocardial infarction in 6, 928 cases and 2, 712 controls in the ISIS case-control study. PLoS Genet 2006, 2:e107.
24. Reuterwall C., Hallqvist J., Ahlbom A., et al. Higher relative, but lower absolute risks of myocardial infarction in women than in men: analysis of some major risk factors in the SHEEP study. J Intern Med 1999, 246:161-174.
25. Samnegard A., Silveira A., Lundman P., et al. Serum matrix metalloproteinase-3 concentration is influenced by MMP-3-1612 5A/6A promoter genotype and associated with myocardial infarction. J Intern Med 2005, 258:411-419.
26. Erqou S., Thompson A., Di Angelantonio E., et al. Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58, 000 participants. J Am Coll Cardiol 2010, 55:2160-2167.
27. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143-3421. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).
28. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110:227-239. National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association.
29. National Academy of Clinical Biochemistry Laboratory Medicine Practice guidelines: emerging biomarkers for primary prevention of cardiovascular disease. Clin Chem 2009, 55:378-384. NACB LMPG Committee Members.
30. Lippi G., Targher G., Guidi G.C. Ginkgo biloba, inflammation and lipoprotein(a). Atherosclerosis 2007, 195:417-418.
31. Schultz O., Oberhauser F., Saech J., et al. Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid disease. PLoS ONE 2010, 5:e14328.